ReviewFrontiers in psychiatry2026
Poststroke anxiety and depression: epidemiology, mechanisms, and management strategies.
Review in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poststroke anxiety and depression (PSAD/PSAnx) are common and heterogeneous emotional disorders among stroke survivors, significantly impacting functional recovery, quality of life, and long term prognosis. Their pathogenesis is complex and multifactorial, involving neurobiological alterations, cognitive dysfunction, behavioral responses, and social environmental factors. Cognitive impairments, functional limitations, and insufficient social support can interact to amplify negative emotional responses, forming a vicious cycle of emotional disorders. Pharmacological interventions remain the cornerstone for moderate to severe cases, with selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) shown to improve mood, cognitive function, and some pain symptoms; individualized dosing and monitoring for adverse effects are essential. Nonpharmacological interventions, including structured rehabilitation, exercise, psychological therapies, and social support, can synergistically enhance neuroplasticity, promote emotional well-being, and improve adherence to rehabilitation. Current evidence is limited by heterogeneous assessment tools, short follow-up periods, and insufficient individualized interventions. Future research should focus on high quality randomized controlled trials, mechanism based stratified management, multimodal interventions, and digital or remote rehabilitation strategies to optimize emotional and functional recovery in stroke survivors. In conclusion, comprehensive interventions targeting PSAD/PSAnx should integrate biological, psychological, and social environmental factors, providing a scientific basis and clinical guidance for improving emotional health, functional restoration, and quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.